AbbVie Inc vs Goodyear Tire & Rubber Co — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Goodyear Tire & Rubber Co trades at $6.1 (market cap $1.74B). The key difference: AbbVie Inc is far larger — about 251.8× Goodyear Tire & Rubber Co's market cap, and AbbVie Inc pays a 2.79% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| ABBV | GT | |
|---|---|---|
Market Cap | $438.19B | $1.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $10.54 |
52-Week Low | $197.38 | $5.58 |
Enterprise Value | $502.45B | $9.09B |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Goodyear Tire & Rubber (GT) is trading at $6.44, down 4.73% today, reflecting ongoing pressure from declining tire volumes and a challenging cost environment. The stock exhibits a bearish technical trend with oversold RSI levels, while fundamentals show a net loss of $1.72 billion in 2025 despite positive cash flow. Recent Q2 2026 results missed earnings expectations but beat revenue estimates, highlighting mixed operational performance amid market headwinds.
The outlook remains cautious with persistent profitability challenges and high debt levels offsetting low valuation multiples. Investment opportunity hinges on volume recovery and cost management improvements, but risks include sustained margin pressure and competitive threats. Analyst sentiment is mixed with a slight hold bias, underscoring the need for operational turnaround to drive shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →